Huge Study Reveals 2 Vaccines That Appear to Reduce Dementia Risk
How the medicine might do that is a mystery scientists are desperate to solve. A new study on two vaccines for older adults gives us a crucial clue.
The retrospective cohort study included more than 130,000 people in the US. It reveals that the shingles vaccine (called Shingrix) and the respiratory syncytial virus (RSV) vaccine (Arexyv) are associated with a reduced risk of dementia compared to the annual flu vaccine.
Related:
Both Shingrix and Arexyv are recommended for older adults, and they contain the AS01 adjuvant, which helps stimulate the immune system after vaccination. The flu vaccine does not.
Because the link to dementia was noticed soon after receiving the jab, it's unlikely that the vaccines' protection from direct viral exposure is behind the dementia link.
Instead, the findings from the University of Oxford suggest "that the AS01 adjuvant itself plays a direct role in lowering dementia risk."
Within 18 months of receiving just the Shingrix vaccine, participants showed an 18 percent reduction in dementia risk compared to those who received only the flu vaccine.
Meanwhile, those who received the RSV vaccine showed a 29 percent reduction in dementia risk compared to the flu vaccine.
Participants who received both the Shingrix and the Arexyv vaccine showed a 37 percent reduction in risk.
This combined effect was not statistically greater than one vaccine on its own. In other words, protection from two viruses didn't significantly increase the protection against dementia.
The findings suggest that some vaccines "protect against dementia through mechanisms unrelated to (or at least in addition to) the prevention of their [target virus]", write the study authors, led by psychiatrist Maxime Taquet from the University of Oxford.
If that's true, then certain vaccines may protect against dementia by triggering important pathways in the immune system.
The conclusions align with an emerging hypothesis: that dementia is not actually a brain disease but a disorder of the immune system within the brain.
Perhaps vaccines can help get that system up and running again, even if a threatening virus never comes along.
In recent years, studies have shown that exposure to several common viruses, like those behind cold sores, shingles, mono, pneumonia, and COVID-19, can lead to a higher risk of cognitive decline down the road. Moreover, vaccines seem to reduce that risk by a significant amount.
But why that is has remained a mystery.
In 2024, for instance, a study from the United Kingdom found that Shingrix delayed dementia onset by 17 percent compared to older, less effective shingles vaccines.
At the time, this was interpreted as indicating that the more effective a shingles vaccine is at reducing viral exposure, the more the brain is protected against cognitive decline.
This older version of the shingles vaccine (called Zostavax), however, doesn't include the AS01 immune-booster, and that may have influenced the results.
In the US, it is generally recommended that adults over the age 50 receive two doses of the shingles vaccine to protect themselves against the varicella-zoster virus. This is the same virus that causes chicken pox, and it can lie latent in the brain for years before re-emerging in adults.
It is also recommended that adults over age 75 receive the RSV vaccine.
Both of these vaccines can protect from dangerous infections, but it seems that may not be all they do.
"It is likely that both the AS01 shingles and RSV vaccines provide some protection against dementia," conclude Taquet and his colleagues.
"The mechanisms underpinning this protection remain to be determined."
Vaccines have saved a staggering 154 million lives around the world in the last half century from deadly viruses.
If we're lucky, that's just the tip of the iceberg.
The study was published in npj Vaccines.
Related News
One Dietary Supplement Shown to Reduce Aggression by Up to 28%
Do Women Need More Sleep Than Men? Here's The Science.
Virus Traces Discovered in The Brain Lining of People With Schizophrenia
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
People Are Reporting A Frightening COVID Symptom — Here's What To Know
A positive COVID-19 test result is not something that anyone wants to see — but now there may be an extra reason to avoid getting sick. COVID infections cause miserable symptoms such as fever, fatigue, congestion and more. Now, though, some people infected with COVID in China are reporting a very sore throat that's been nicknamed 'razor blade throat.' According to Google trends data, people throughout the U.S. are now, too, worried about this scary-sounding symptom and are searching for things like 'new covid variant painful symptom' and 'covid razor throat.' Just how worried do you need to be about a super-painful sore throat during a COVID infection? Below, doctors weigh in on the supposed 'razor blade' sore throat symptom: Some people with COVID are reporting a 'razor blade throat,' but you don't need to panic. It's nothing new. 'In the past, as new variants have come on the scene, there almost invariably have been questions about distinctive symptoms, and after a while, when you gather a lot of data, turns out not to be the case — all of these symptoms have occurred before,' said Dr. William Schaffner, a professor of preventive medicine in the department of health policy at Vanderbilt University Medical Center in Nashville, Tennessee. Meaning, the circulating COVID variants tend to produce the same sort of symptoms and disease as the ones from years ago, Schaffner added. 'Although the more recent variants, these omicron variants, are less severe,' he said. A very sore throat isn't specific to the circulating COVID variants, said Dr. Carrie Horn, the chief medical officer and chief of the division of hospital and internal medicine at National Jewish Health in Colorado. Instead, it's a symptom that has been associated with COVID infections for a while, Horn said. Schaffner had not heard of the 'razor blade' sore throat symptom particularly, but has heard of people having a severe sore throat with COVID infections. While some people can have a very sore throat that could be described as razor-like, it doesn't mean it's going to happen to everyone — and it also isn't some new, scary symptom that is associated with new COVID infections. There is not one outstanding COVID symptom that marks an infection, said Dr. Mark Burns, an infectious disease expert at UofL Health in Louisville, Kentucky. 'A sore throat is a symptom of this, but also fever and cough and fatigue, these are all symptoms as well,' Burns added. 'To sum it all up, the symptoms, including sore throat, are really no different. There's no increased intensity based on sore throat or anything like that,' added Burns. Here's how you can protect yourself from a COVID infection: COVID tends to surge twice a year — once in the winter and once in the mid-to-late summer, Schaffner said. 'And so there has been a longstanding recommendation by the CDC's Advisory Committee on Immunization Practices that people who are at increased risk of getting severe COVID should actually get two COVID vaccinations a year. Obviously, one in the fall to prevent the winter increase, but another right now in order to help prevent serious disease during the late summer and early fall,' Schaffner said. This goes for people 65 and older, younger people with underlying chronic medical conditions and pregnant people, he said. 'The recommendation is take special precautions and get that extra dose, because if we get infected ... we get that extra protection and to help keep us out of the hospital,' Schaffner said. Wearing a mask in indoor spaces, social distancing, washing your hands often and increasing ventilation when possible are more ways to protect yourself from COVID and other respiratory viruses, too, said Burns. If you do get sick, there are treatments available. If you have any COVID symptoms, such as sore throat, fatigue, cough or fever, take a test to see if you have COVID. If you are infected, get in touch with your doctor, particularly if you're high-risk as there are treatments available, said Schaffner. It's important that you talk to your primary care provider as the guidance will vary depending on your age, underlying conditions and other risk factors. COVID is a miserable infection, Horn added. 'Over-the-counter meds help — Ibuprofen alternating with Tylenol, if you're able to take those ... there's no reason to be miserable,' Horn said. 'So, take the medicine that you are able to take to help,' she said. It's also important to stay hydrated when you're sick even if you do have a painful sore throat. A sore throat can make hydration feel like more of a chore, but it's important to drink water and herbal teas as dehydration can further irritate the dry membranes in your throat, Horn said. 'If you are sick, it's best to keep your germs to yourself,' said Horn. This means canceling the dinner plans, not going to the party and calling out of work if you can — if you can't, wearing a tight-fitting mask is key, Horn added. 'Preventing transmission is the biggest thing that we can do to help keep everybody healthy,' Horn said. Related... A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms RFK Jr. Wants To Take COVID Shots Away From Pregnant People — But You Can Fight Back CDC Changes COVID Vaccine Recommendations — But Doesn't Go As Far As RFK Jr. Wanted
Yahoo
2 hours ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Wall Street Journal
5 hours ago
- Wall Street Journal
A Cosmic Mystery: Is China Building the World's Biggest Telescope?
Astronomer Robert Kirshner investigates some of the universe's biggest questions: What happens when a star explodes? Is the universe still expanding? He recently added a new mystery to the list: Is China quietly building the world's biggest telescope? He would like to know, because he leads a rival telescope project in the U.S.
